Local Facilitator and Chair:
avefdvfvvafesvds
vdfsvfzv dfvzfx
Consultant in Infectious Diseases and General Medicine, NHS Greater Glasgow and Clyde, UK
Andrew graduated from Aberdeen in 1989 and trained in General Medicine/ infectious diseases in Dundee and Papua New Guinea. He was appointed consultant physician in Glasgow in 2000 and he is an Honorary Professor in the University of Glasgow. He established and leads the NHS Greater Glasgow and Clyde OPAT service and Antimicrobial Management Team. He Chairs the Scottish Antimicrobial Prescribing Group and is a member of the Scottish Government urgent and unscheduled care virtual capacity / hospital at home expert advisory group. He co-leads the BSAC OPAT initiative and co-produced the BSAC OPAT MOOC on future learn. He has >160 peer reviewed publications.
B. Braun is one of the world’s leading providers and manufacturers of healthcare solutions today.
Every service that B. Braun provides incorporates the entirety of our knowledge and skills, the company’s deep understanding of users’ needs, and extensive expertise since 1839.
With its constantly growing portfolio of effective medical care solutions, B. Braun makes a substantial contribution towards protecting and improving people’s health.
By offering supplementary services and consulting, B. Braun is a system supplier that develops the best solution for patients in close partnership with our customers, making a
significant contribution to medical advancements.
System partnerships, relationships and earnings are the core themes which are to be pursued in all divisions and regions, with the support of the centralised units and departments.
The goal is to grow together in order to ensure that our company will be able to operate independently in the current strategic period. This will allow us in the future to continue making
a contribution to protecting and improving the health of people all over the world.
Visit sponsor websiteBIOPATCH® is an antimicrobial sponge dressing providing 7-day release of Chlorhexidine Gluconate. It is indicated to reduce local infections, catheter-related blood stream infections (CRBSI), and skin colonization of microorganisms commonly related to CRBSI from vascular and non-vascular percutaneous devices. BIOPATCH® can help improve patient outcomes, reduce hospital costs and reduce CRBSIs.
Visit sponsor websiteHorizon Strategic Partners (HSP) was established in 2008 to provide IT Consultancy Services to the Department of Health. Since then it has developed a range of mobile healthcare solutions that are used in over 50% of all UK Acute Hospital Trusts.
HSP has worked with the BSAC over a number of years on various IT projects, such as the development of the OPAT National Outcomes Registry which provides the most comprehensive overview of OPAT service provision in the UK. Recently HSP has worked with PHE to develop a Point Prevalence Survey (PPS) System that was used on a national basis to collect data for the 2016 ECDC survey of healthcare-associated infections and antimicrobial use in acute care hospitals.
In 2017 HSP took over the IPR and development of the OPAT Patient Management System (PMS), with an upgraded system being launched in 2018.
Visit sponsor websitePlease submit your abstract(s) using the online submission form for consideration for POSTER presentation at the OPAT Workshops.
All accepted abstracts will be published in JAC-Antimicrobial Resistance
The deadline for abstract submission for the Birmingham and Glasgow workshops is 1700hrs BST on Friday 9 May 2025
The deadline for abstract submission for the London, Belfast, London (paediatric) and Bristol workshops is 1700hrs BST on Friday 8 August 2025.
Please note our Conditions of Submission:
By submitting the abstract you confirm, and on behalf of any co-contributors, the following:
a) to publish the final version of the conference abstract in JAC-Antimicrobial Resistance, and to distribute it and/or to communicate it to the public, either within the Journal, on its own, or with other related material throughout the world, in printed, electronic or any other format or medium whether now known or hereafter devised;
b) to make translations of the abstract and to distribute them to the public; to authorise or grant licenses to third parties to do any of the above;
c) to deposit copies of the abstract in online archives maintained by OUP or by third parties authorised by OUP; and
d) to administer subsidiary rights agreements with third parties for the full period of copyright and all renewals, extensions, revisions and revivals.
Format of Abstracts:
Abstracts should be no longer than 500 words and contain:
For example, standard headings are Background (optional), Objectives, Patients and methods (or Methods), Results, and Conclusions.
For any queries regarding abstract submissions, please contact Esme Carruthers.